<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26577">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01694615</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00052081</org_study_id>
    <nct_id>NCT01694615</nct_id>
  </id_info>
  <brief_title>Cryoprobe Transbronchial Lung Biopsy in Lung Transplant Patients</brief_title>
  <official_title>Prospective Controlled Study of Transbronchial Cryoprobe Versus Forceps Biopsy for Acute Rejection in Lung Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lung transplant recipients undergo bronchoscopy with biopsies for clinical indications and
      for surveillance in the diagnosis of acute rejection using standard transbronchial forceps.
      It is recognized that standard forceps biopsies underestimate the presence or degree of
      airway rejection due to crush artifact and sample size. Transbronchial cryobiopies have been
      shown in the literature to provide larger samples without crush artifact in a safe fashion
      in lung cancer patients. The aim of this study is to determine if transbronchial cryobiopsy
      is superior to standard transbronchial forceps biopsies in regards to sample size,
      architecture and the diagnosis of early rejection in lung transplant recipients which if
      discovered earlier may improve survival.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2011</start_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Differences in size of biopsy specimen and architectural preservation of the airways/alveoli (ie degree of crush artifact)</measure>
    <time_frame>From date of study enrollment until the patient is 2 years post lung transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Direct measurements of pathologic specimens from the forceps and cryoprobe will be compared. In addition, amount of crush artifact will alse be directly measured and compared utilizing pathology software which measures area of viable tissue.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic yield (ie presence of ACR, chronic rejection, lymphocytic bronchiolitis and infection)</measure>
    <time_frame>From date of study enrollment until the patient is 2 years post lung transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Each specimen will be independently reviewed by a lung transplant pathology physician to determine the presence or absence of rejection and results compared. All data will be available to the transplant team in the event any rejection is found, it will be acted upon immediately as per the transplant teams protocol.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">91</enrollment>
  <condition>Lung Transplantation</condition>
  <arm_group>
    <arm_group_label>Cryoprobe biopsy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients enrolled will undergo standard forceps biopsies followed by cryoprobe biopsies and results will be compared</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Forceps Biopsy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients enrolled will undergo standard forceps biopsies followed by cryoprobe biopsies and results will be compared</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryoprobe biopsy</intervention_name>
    <description>none</description>
    <arm_group_label>Cryoprobe biopsy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Forceps Biopsy</intervention_name>
    <arm_group_label>Forceps Biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals referred for either clinically indicated or surveillance flexible
             bronchoscopy will be included in the study population

          -  Age greater than 18 years and having undergone bilateral orthotopic lung
             transplantation

        Exclusion Criteria:

          -  Coagulopathy: plts &lt; 50K, INR &gt; 1.5

          -  FEV1 &lt; 0.8

          -  Diffuse bullous disease

          -  Hemodynamic instability

          -  Severe hypoxemia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lonny Yarmus</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lonny Yarmus</last_name>
    <email>lyarmus@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lonny Yarmus</last_name>
      <email>lyarmus@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Lonny Yarmus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hopkinsmedicine.org/ip</url>
  </link>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 12, 2014</lastchanged_date>
  <firstreceived_date>September 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Lonny Yarmus</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Lung Transplantation</keyword>
  <keyword>Acute Rejection</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
